First trial of the HIV-1 vaccine in Africa: Ugandan experience

摘要: Problems in setting up the first trial of an HIV-1 vaccine Uganda are described here by Mugerwa and colleagues. The authors explain how they solved these problems give suggestions to help researchers who starting future trials HIV vaccines Trials have been conducted Europe, North America, Brazil, China, Thailand.1 a candidate Africa was recently completed Uganda. It involved randomised, placebo controlled healthy volunteers at low risk infection. 2 3 vaccine, called “ALVAC-HIV,” uses live recombinant canarypox vector express envelope core genes HIV-1. Many commentators predicted that it would be difficult conduct vaccines developing countries because scientific, sociobehavioural, ethical, logistical barriers.4–8 Before we started Uganda, gathered data us overcome potential barriers. We collected epidemiological9 sociobehavioural10 about people had participated studies looked preparing for vaccine. These showed prevalence incidence HIV, behaviours placing becoming infected with social acceptability against HIV.9–11 received detailed education counselling infection vaccines, recruited some our trial.11 organised three open workshops workshop Kampala 1996 gain consensus from scientists, policy makers, community representatives, media undertake research into vaccines. Despite initiatives solve before began, still encountered many In this article, discuss barriers …